Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT04384484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Study identification
- NCT ID
- NCT04384484
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 440 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2020 (Actual)
- Primary completion
- Mar 31, 2026 (Actual)
- Completion
- Jun 30, 2028 (Estimated)
- Last update posted
- Apr 28, 2026
2020 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Redlands Community Hospital | Redlands | California | 92373 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| UnityPoint Health - Iowa Oncology Research Association (IORA) | Des Moines | Iowa | 50309 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Comprehensive Cancer Centers of Nevada - Henderson | Las Vegas | Nevada | 89169 | — |
| Kaiser Permanente Interstate Medical Office Central | Portland | Oregon | 97227 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Virginia Cancer Specialists | Gainesville | Virginia | 20155 | — |
| Medical College of Wisconsin Cancer Center Clinical Trials Office | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 133 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04384484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04384484 live on ClinicalTrials.gov.